Zhenyu Li and team’s research suggests physicians may need to closely monitor patients with elevated BNP and consider whether antiplatelet therapy could help prevent or reduce the risk of blood clots and related complications.
Zhenyu Li and team’s research suggests physicians may need to closely monitor patients with elevated BNP and consider whether antiplatelet therapy could help prevent or reduce the risk of blood clots and related complications.
The Neuroguard IEP 3-in-1 system was previously studied for transfemoral and transradial carotid stenting in the PERFORMANCE I and PERFORMANCE II studies. It received FDA PMA approval in October 2024 and is commercially distributed by...
The Neuroguard IEP 3-in-1 system was previously studied for transfemoral and transradial carotid stenting in the PERFORMANCE I and PERFORMANCE II studies. It received FDA PMA approval in October 2024 and is commercially distributed by...
Cambridge, MA – Blackstone Life Sciences (BXLS) announced a $455 million collaboration with Boston Scientific Corporation to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The...
Cambridge, MA – Blackstone Life Sciences (BXLS) announced a $455 million collaboration with Boston Scientific Corporation to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The...
The 563-patient blinded study found that HearO predicted more than 70% of heart failure events at an average of 24.6 days before they occurred, with high patient compliance and no device-related adverse events.
The 563-patient blinded study found that HearO predicted more than 70% of heart failure events at an average of 24.6 days before they occurred, with high patient compliance and no device-related adverse events.
Amgen announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with atherosclerotic cardiovascular disease...
Amgen announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with atherosclerotic cardiovascular disease...
Compared with usual care based on stress testing, care guided by AI-based quantitative coronary CT analysis (AI-QCT) improved diagnostic certainty and led to more patients receiving lipid-lowering therapy.
Compared with usual care based on stress testing, care guided by AI-based quantitative coronary CT analysis (AI-QCT) improved diagnostic certainty and led to more patients receiving lipid-lowering therapy.
Patients with acute myocardial infarction complicated by cardiogenic shock who received intravenous cangrelor had less microvascular obstruction and greater recovery of left ventricular function than those receiving crushed oral ticagrelor,...
Patients with acute myocardial infarction complicated by cardiogenic shock who received intravenous cangrelor had less microvascular obstruction and greater recovery of left ventricular function than those receiving crushed oral ticagrelor,...
